Alzheimer's disease & Multi-infarct dementia
50-200 mcg PO BID
Senile or presenile dementia
30 mcg PO BID
Prevention of muscle weakness in myasthenia gravis
400 mcg IM qDay
Improve memory; treatment of Alzheimer's disease, protection from neurotoxic agents including organophosphate nerve gases, glutamate toxicity, and treating myasthenia gravis
Clinical studies in progress; preliminary results promising
Serious - Use Alternative
Significant - Monitor Closely
Frequency Not Defined
Gastrointestinal effects (eg, nausea, diarrhea)
See cholinergic syndrome
Seizure disorders, cardiac arrhythmias, asthma, IBS, IBD & malabsorption syndromes
Pregnancy & Lactation
Pregnancy Category: avoid
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Absorption: readily from GI tract
Distribution: wide, including brain
Peak Plasma Time: 80 min
Metabolism: some first pass metabolism in liver
Mechanism of Action